Metreleptin, a leptin analog, is an FDA-approved drug for generalized lipodystrophy and is not approved in other forms of lipodystrophy [17]. Metreleptin decreases hyperphagia, improves glycemic and lipid parameters and hepatic steatosis, reduces cardiovascular risk, promotes normal pubertal progression, and improves fertility [18]. The gene discussed is LEP; the disease is lipodystrophy.